Tau Biosensor CRISPR Screening for Genetic Modifier Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying genetic modifiers of tau aggregation are limited in sensitivity and specificity, hindering the understanding of neurodegenerative diseases and therapeutic intervention.
Innovation Solution
A CRISPR-based screening platform is developed, utilizing FRET pairs and flow cytometry to identify genetic modifiers by culturing cells with a tau seeding agent, forming aggregates, and analyzing guide RNA abundance to determine gene disruption or activation effects on tau aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CRISPR interference (CRISPRi) is used to knock down target genes, then gene expression is reduced, but the method lacks sensitivity and specificity in identifying genetic modifiers of tau aggregation
Solution Approach 1:
The patent introduces FRET-based biosensors as intermediaries between gene disruption and aggregation detection. The biosensors convert molecular interactions into optical signals, enabling precise measurement of tau aggregation in response to CRISPR-mediated gene disruption, thereby improving identification accuracy while maintaining screening reliability
Solution Approach 2:
The patent replaces traditional mechanical or chemical detection methods with optical detection using FRET (fluorescence resonance energy transfer). This substitution enables non-invasive, real-time monitoring of tau aggregation with high sensitivity and specificity, resolving the contradiction between measurement precision and screening reliability
2Measurement precision
If FACS screening is used to detect intracellular tau aggregates, then aggregation can be detected, but the method requires cell membrane perforation which reduces cell viability and measurement accuracy
Solution Approach 1:
The patent uses FRET-based biosensors as intermediaries that can detect tau aggregation through intact cell membranes. The optical signals generated by FRET allow aggregation detection without requiring membrane perforation, thereby eliminating cell damage while maintaining detection accuracy
Solution Approach 2:
The patent substitutes mechanical membrane perforation with optical detection methods. FRET-based fluorescence microscopy or flow cytometry can detect aggregation through live cells without physical disruption, replacing the harmful mechanical intervention with a non-invasive optical measurement
3Adaptability or versatility
If genome-wide CRISPR screening is performed to identify genetic modifiers, then comprehensive gene coverage is achieved, but the complexity of the platform increases
Solution Approach 1:
The patent creates a universal FRET-based biosensor platform that can be applied across genome-wide CRISPR screens. The biosensors are designed to work with various CRISPR methods (knockout, knockdown, activation) and can detect tau aggregation in multiple cell types, providing multi-functionality that simplifies the overall screening platform while maintaining genome-wide coverage capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform effectively identifies genes that prevent or enhance tau aggregation, providing insights into disease progression and potential therapeutic targets.
Implementation Method 1
the first reporter and the second reporter are fluorescent proteins, wherein the first reporter and the second reporter are a fluorescence resonance energy transfer (FRET) pair
Implementation Method 2
the aggregation-positive population of cells and the aggregation-negative population of cells in step (e) is identified by flow cytometry
Data Source
Figure 1~2
Figure 3A
Figure 3B
AI summary
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.